Exhibit 99.1

LOGO

scPharmaceuticals Inc. Reports Second Quarter 2025 Financial

Results and Provides Business Update

Generated net FUROSCIX^® revenue of $16 million in the second quarter of 2025; up 99% over Q2 2024

Doses shipped to patients increased 45% over Q1 2025 and 117% over Q2 2024

Launch of FUROSCIX in chronic kidney disease

Autoinjector remains on track for sNDA submission in Q3 2025; designed to reduce treatment time from five hours to less than ten seconds

Cash and cash equivalents of $40.8 million as of June 30, 2025

Investor conference call and webcast today, Thursday, August 7^th, at 4:30pm ET

BURLINGTON, Mass., August 7, 2025 (GLOBE NEWSWIRE) – scPharmaceuticals Inc. (Nasdaq: SCPH) (the “Company”), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations, today reported financial results for the second quarter ended June 30, 2025, and provided a business update.

“We’re very pleased with the continued momentum behind FUROSCIX, with net revenue of $16 million in the second quarter. We believe this growth reflects strong execution across our organization and increasing adoption by prescribers who recognize the clinical and economic value that FUROSCIX brings to patient care,” said John Tucker, Chief Executive Officer of scPharmaceuticals. “Expanding FUROSCIX into the chronic kidney disease (CKD) market represents a critical step forward in our mission to transform how diuretic therapy is delivered. Nephrologists are on the front lines of managing fluid overload in their CKD patients, both with and without concomitant heart failure, and we believe FUROSCIX offers them a much-needed tool to address this challenge.”

“We are encouraged that the Ambulatory Specialty Model (ASM), aimed at improving the upstream management of heart failure, was proposed in the 2026 Physician Fee Schedule by the Centers for Medicare and Medicaid Services on July 14, 2025. The ASM will test whether adjusting Medicare Part B payments for cardiologists based on their performance on targeted quality measures results in enhanced quality of care and reduced costs. By shifting accountability from the hospital to the clinical specialist for all unplanned heart failure hospitalizations, not just 30-day readmissions, with a specific reference to early intervention for worsening symptoms, we believe that this new ASM program has the potential to be a tailwind to the already successful uptake for FUROSCIX.”

LOGO

Business Update

•

For the second quarter ended June 30, 2025, scPharmaceuticals reports:

•

Net FUROSCIX revenue of $16.0 million, compared to $8.1 million for the second quarter of 2024, representing approximately 99% annual growth

•

Approximately 20,200 FUROSCIX doses filled compared to approximately 9,300 doses filled in the second quarter of 2024, representing approximately 117% annual growth

•

Sales to Integrated Delivery Networks increased 70% in the second quarter of 2025 compared to the first quarter of 2025

•

Gross-to-net (GTN) discount of 27% for the second quarter of 2025 compared to 23% for the first quarter of 2025

•

Approximately 4,700 unique prescribers have prescribed FUROSCIX from launch through the end of the second quarter of 2025

•

FUROSCIX CKD Indication Expansion Launch: In late April 2025, scPharmaceuticals formally launched FUROSCIX for the treatment of edema in patients with CKD, and prescriptions are currently being written by nephrologists in the expanded indication.

•

80mg/1mL FUROSCIX Autoinjector: the SCP-111 program, which is designed to reduce administration time from five hours to less than ten seconds, is on track for a targeted sNDA filing in the current quarter.

Second Quarter 2025 Financial Results

Product revenues were $16.0 million for the second quarter of 2025, compared to $8.1 million for the second quarter of 2024. Costs of product revenues were $5.0 million for the second quarter of 2025, compared to $2.3 million for the second quarter of 2024. The increase in both product revenues and costs of product revenues for the quarter ended June 30, 2025, was due to an increase in demand for FUROSCIX further into the commercial launch, and related manufacturing costs.

Research and development expenses were $4.1 million for the second quarter of 2025, compared to $2.7 million for the second quarter of 2024. The increase in research and development expenses for the quarter ended June 30, 2025, was primarily due to an increase in device development costs, pharmaceutical development costs and employee-related costs. The increase was partially offset by a decrease in clinical study costs.

Selling, general and administrative expenses were $21.2 million for the second quarter of 2025, compared to $17.5 million for the second quarter of 2024. The increase in selling, general and administrative expenses for the quarter ended June 30, 2025, was primarily due to an increase in employee related costs, commercial costs, and professional service costs. The increase was partially offset by a decrease in patient support costs.

scPharmaceuticals reported a net loss of $18.0 million for the second quarter of 2025, compared to $17.1 million for the second quarter of 2024.

LOGO

As of June 30, 2025, scPharmaceuticals’ total shares outstanding was 53,290,227.

Conference Call and Webcast Information

scPharmaceuticals’ management will host a conference call and webcast to review the Company’s second quarter 2025 results today, Thursday, August 7, at 4:30 p.m. ET.

A link to the live webcast can be found here.

Participants should dial (800) 715-9871 (toll-free) or (646) 307-1963 (toll) and use the passcode 4965353.

The live webcast and replay of the conference call can be accessed here or under “News & Events” in the Investor Relations section of the Company’s website, www.scpharmaceuticals.com.

INDICATION

FUROSCIX^® (furosemide injection), 80 mg/10 mL for subcutaneous use is indicated for the treatment of edema (i.e., congestion, fluid overload, or hypervolemia) in adult patients with chronic heart failure or chronic kidney disease (CKD), including the nephrotic syndrome.

IMPORTANT SAFETY INFORMATION

FUROSCIX is contraindicated in patients with anuria and in patients with a history of hypersensitivity to furosemide, any component of the FUROSCIX formulation, or medical adhesives.

Furosemide may cause fluid, electrolyte, and metabolic abnormalities, particularly in patients receiving higher doses, patients with inadequate oral electrolyte intake, and in elderly patients. Serum electrolytes, CO₂, BUN, creatinine, glucose, and uric acid should be monitored frequently during furosemide therapy.

Excessive diuresis may cause dehydration and blood volume reduction with circulatory collapse and possibly vascular thrombosis and embolism, particularly in elderly patients.

Furosemide can cause dehydration and azotemia. If increasing azotemia and oliguria occur during treatment of severe progressive renal disease, discontinue furosemide.

Cases of tinnitus and reversible or irreversible hearing impairment and deafness have been reported with furosemide. Reports usually indicate that furosemide ototoxicity is associated with rapid injection, severe renal impairment, the use of higher than recommended doses, hypoproteinemia or concomitant therapy with aminoglycoside antibiotics, ethacrynic acid, or other ototoxic drugs.

LOGO

In patients with severe symptoms of urinary retention (because of bladder emptying disorders, prostatic hyperplasia, urethral narrowing), the administration of furosemide can cause acute urinary retention related to increased production and retention of urine. These patients require careful monitoring, especially during the initial stages of treatment.

Contact with water or other fluids and certain patient movements during treatment may cause the On-body Infusor to prematurely terminate infusion. Ensure patients can detect and respond to alarms.

The most common adverse reactions with FUROSCIX administration in clinical trials were site and skin reactions including erythema, bruising, edema, and injection site pain.

Please see the full Prescribing Information (https://www.furoscix.com/wp-content/uploads/prescribing-information.pdf) and Instructions for Use ( https://www.furoscix.com/wp-content/uploads/instructions-for-use.pdf)

About scPharmaceuticals

At scPharmaceuticals, we are powered by passion, driven by patient care. Our mission is focused on advancing cardiorenal care through innovative, integrated treatments that address unmet patient needs.

Our goal is to become the foremost advocate for patient-centric cardiorenal care, driving global health improvements through specialized, multidisciplinary approaches. scPharmaceuticals is expanding its reach, offering integrated therapies and products that address diverse healthcare needs and potentially improve the lives of our patients. scPharmaceuticals is headquartered in Burlington, MA. For more information, please visit www.scPharmaceuticals.com.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, statements regarding the development and commercialization of products, such as the Autoinjector, and its potential to increase patient care and the treatment of fluid at home; the anticipated submission of a sNDA for 80mg/1mL FUROSCIX Autoinjector in the third quarter of 2025; our commercial strategy for FUROSCIX and anticipated sales; the impact of our ongoing expansion efforts; the impact of ASM program; our participation in upcoming events and presentations; and the timing of any of the foregoing. Any forward-looking statements in this press release are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include but are not limited to, our dependence on the commercial success of FUROSCIX and, if approved, our other product candidates; risks related to the receipt of regulatory approval for our product candidates; risks related to our ability to manufacture, or

LOGO

the ability of third parties to deliver, sufficient product for commercialization of FUROSCIX or any of our product candidates, if approved; risks related to our history of operating losses, we have a history of significant operating losses and expect to incur significant and increasing losses for the foreseeable future; we may never achieve or maintain profitability; we may need additional funding and may be unable to raise capital when needed, which would force us to delay, reduce or eliminate our product development programs or commercialization efforts; the terms of our credit facility and revenue participation financing facility place restrictions on our operating and financial flexibility, and we may not have cash available to us in an amount sufficient to enable us to make interest or principal payments on our indebtedness when due; clinical and preclinical development involves a lengthy and expensive process with an uncertain outcome, and any difficulties or delays in the commencement or completion, or the termination or the potential for the results from any clinical trials to support submission of sNDAs or comparable regulatory applications; and the risk that global economic factors and uncertainties will impact the Company’s operations. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the sections entitled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, on file with the Securities and Exchange Commission, available at the Securities and Exchange Commission’s website at www.sec.gov, as well as discussions of potential risks, uncertainties and other important factors in the Company’s subsequent filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and the Company undertakes no duty to update this information unless required by law.

Katherine Miranda

scPharmaceuticals Inc., 781-301-6869

kmiranda@scpharma.com

Investors:

Matthew Beck

astr partners, (917) 415-1750

matthew.beck@astrpartners.com

scPharmaceuticals Inc.

Unaudited Consolidated Statements of Operations

(in thousands, except share and per share data)


	THREE MONTHS ENDED JUNE 30,						SIX MONTHS ENDED JUNE 30,
	2024			2025			2024			2025
Product revenues, net	$	8,054		$	16,041		$	14,156		$	27,793
Operating expenses:
Cost of product revenues		2,300			5,011			4,085			8,482
Research and development		2,677			4,098			5,403			8,729
Selling, general and administrative		17,508			21,226			34,955			42,633

Total operating expenses		22,485			30,335			44,443			59,844

Loss from operations		(14,431	)		(14,294	)		(30,287	)		(32,051	)
Change in fair value of term loan		—			(150	)		—			150
Change in fair value of revenue purchase and sale liability		—			(2,560	)		—			(4,312	)
Other (expense) income		(1,189	)		(128	)		1,783			8
Interest income		664			509			1,541			1,225
Interest expense		(2,134	)		(1,401	)		(4,235	)		(2,786	)

Net loss	$	(17,090	)	$	(18,024	)	$	(31,198	)	$	(37,766	)

Net loss per share, basic and diluted	$	(0.44	)	$	(0.34	)	$	(0.80	)	$	(0.70	)

Weighted—average common shares outstanding, basic and diluted		38,984,745			53,719,662			38,968,438			53,698,138

scPharmaceuticals Inc.

Unaudited Consolidated Balance Sheet Data

(in thousands)


	DECEMBER 31, 2024			JUNE 30, 2025
Cash and cash equivalents	$	75,655		$	40,809
Working capital		90,973			58,299
Total assets		107,519			80,255
Term loan		51,350			51,200
Revenue purchase and sale liability		26,869			28,957
Accumulated deficit		(366,494	)		(404,260	)
Total stockholders’ equity (deficit)		13,320			(21,316	)

scPharmaceuticals Inc. 8-K